Actualités sur Medizin, Gesundheit

Byondis B.V.

Byondis and medac Enter Into License and Collaboration and Supply Agreements for Anti-HER2 ADC Trastuzumab Duocarmazine (SYD985)

Nijmegen, Netherlands and Wedel, Germany (ots/PRNewswire) - SYD985 Marketing Authorization Application Soon to Be Submitted to the EMA Byondis B.V., an independent, Dutch clinical stage biopharmaceutical company creating precision medicines, has entered into a License and Collaboration Agreement and a Supply ...

Chiesi Farmaceutici S.p.A.

Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH

Parma, Italy, and Cleveland, Ohio (ots/PRNewswire) - - New investment will progress treatment of pulmonary arterial hypertension (PAH), a rare condition which causes high blood pressure in the blood vessels that supply the lungs and can lead to heart failure. - Current approved medications mainly address the ...

Hikma Pharmaceuticals PLC

Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals

London (ots/PRNewswire) - Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK. About Hikma ...

REVEAL GENOMICS, S.L.

REVEAL GENOMICS®️ ANNOUNCES RESEARCH COLLABORATION IN HER2+ BREAST CANCER

Barcelona, Spain (ots/PRNewswire) - - The agreement with Dana-Farber Cancer Institute consists of using HER2DX®️ to analyze tumor samples from more than 500 patients with early-stage HER2+ breast cancer across three clinical trials (APT, ATEMPT, and DAPHNE). - The three completed studies were essential in establishing new anti-HER2-based treatment strategies for ...

Novaliq GmbH

NOVALIQ PRESENTS DATA FROM SECOND PHASE 3 TRIAL OF INVESTIGATIONAL TREATMENT CYCLASOL® (0.1% CYCLOSPORINE OPHTHALMIC SOLUTION) AT THE AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY ANNUAL MEETING

Heidelberg, Germany, and Cambridge, Mass. (ots/PRNewswire) - Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced that data from the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investigational ...

Schweizerischer Nationalfonds / Fonds national suisse

Weather data predict risk of hospital congestion

Bern (ots) - A team of researchers supported by the Swiss National Science Foundation has developed a mathematical model that anticipates flu peaks in hospitals based on weather data. When too many people fall ill at the same time, hospitals run the risk of congestion, as the Covid-19 pandemic showed to a certain extent. The flu virus can cause the same problems. A team of researchers supported by the Swiss National ...

Bendit Technologies

BENDIT Technologies Receives U.S. Food and Drug Administration 510(k) Clearance of its Bendit 021" steerable microcatheter

Tel Aviv, Israel (ots/PRNewswire) - BENDIT Technologies, a company focused on the development of a steerable microcatheter platform, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Bendit21 microcatheter for treatment in the neuro, peripheral, and coronary ...

Micreos

Micreos Pharmaceuticals announces success of its XZ.700 technology in selectively eliminating Staphylococcus aureus pathogen without triggering resistance

Zug, Switzerland (ots/PRNewswire) - In a new publication, the company's flagship compound proves effective in targeting the harmful pathogen while preserving a healthy microbiome Micreos Pharmaceuticals today announces findings from a study proving the effectiveness of XZ.700, a novel antibacterial enzyme, in ...

TauRx Pharmaceuticals Ltd

TauRx's late-stage clinical trial reaches new milestone

Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Significant milestone in the only late-stage clinical trial targeting tau pathology of Alzheimer's - TauRx on track to announce top line results in May - Trial aims to confirm efficacy of first tau-based treatment for Alzheimer's TauRx Pharmaceuticals Ltd, a global leader in tau-based Alzheimer's Disease (AD) research, has announced that the last patient has completed ...

Oxitec Ltd.

Oxitec's Malaria Program Receives New Investment to Expand to Pilot Phases in Two Malaria-Affected Regions

Oxford, England (ots/PRNewswire) - - Oxitec's team of experts will advance development and pilot validation of the Friendly™ mosquito platform to combat two malaria-spreading mosquitoes: the invasive Anopheles stephensi, predicted to cause urban malaria epidemics across Africa; and Anopheles albimanus, which is ...

Debiopharm International SA

DEBIOPHARM ANNOUNCES ONCOLOGY RESEARCH ADVANCEMENTS AT AACR 2022 FOR NOVEL CANCER COMPOUNDS AND DRUG DELIVERY TECHNOLOGIES

Mindtree

Mindtree Invests in COPE Health Solutions to Accelerate its Healthcare Business

New York (ots/PRNewswire) - Mindtree, a global technology services and digital transformation company, today announced that it has made a strategic investment in COPE Health Solutions, a leading U.S. healthcare consulting, implementation, and co-management leader in value-based care and payment, workforce development and data analytics, to expand its healthcare ...

Schweizerischer Nationalfonds / Fonds national suisse

Show me your posts, and I'll tell you if you're burned out

Bern (ots) - Artificial intelligence helps to detect burnout. Researchers supported by the Swiss National Science Foundation have developed a promising technique based on automatic analysis of text data. Burnout refers to a state of profound physical and mental exhaustion. It is difficult to detect because its symptoms can overlap with those of depression and anxiety. But artificial intelligence may hold the key to better ...

News Direct

Lancer Dermatology Announces Partnership with Forefront Dermatology

Beverly Hills, CA (ots) - --News Direct-- Premier Beverly Hills-based dermatology practice, Lancer Dermatology, announced today that it has partnered with Forefront Dermatology, the largest physician-led single specialty group providing dermatological services in the United States with over 200+ dermatology practices. The collaboration with Forefront Dermatology will ...

Chiesi Farmaceutici S.p.A.

CHIESI GROUP CONTINUES GROWTH

Parma, Italy (ots/PRNewswire) - - 2021 Turnover €2.42bn - up 8.6% - Internationally China up 22%, US up >10% - Continued focus on innovation: almost 20% of turnover invested in R&D - Chiesi recognised as Top Employer in eight markets and as Top Employer Europe for 10th consecutive year Growth continues at Chiesi, the international research-focussed pharmaceutical group and its 30 global affiliates with turnover at €2.42bn, up 8.6% vs 2020. Gross operating profit (EBITDA) ...

FDI World Dental Federation

2

FDI World Dental Federation launches Consensus Statement on Sustainable Oral Healthcare / Paving the way for an industry Code of Good Practice

Debiopharm International SA

VIVOSENSE ANNOUNCES CLOSING OF $25M SERIES A FINANCING

Newport Beach (ots) - Proceeds to accelerate the collection and use of wearable sensor data in clinical trials along with the development of novel digital biomarkers Funding round co-led by the Perceptive Xontogeny Venture (PXV) Fund and Switzerland-based Debiopharm Innovation Fund VivoSense, Inc., (“VivoSense”) an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor ...

Lumanity

Lumanity Acquires Innovative Edge

New York (ots/PRNewswire) - Creating an end-to-end pharmaceutical product commercialization and launch excellence capability that optimizes and accelerates patient access to medical advances Lumanity today announced the acquisition of Innovative Edge ("IE"), a leading provider of pharmaceutical product launch services. The terms of the transaction were not disclosed. IE partners with world-leading biopharma companies – from Top 20 pharmaceutical manufacturers to ...

CartiHeal

FDA approves CartiHeal's Implant for the Treatment of Cartilage and Osteochondral Defects

Kfar Saba, Israel (ots/PRNewswire) - Approval is based on results of a multicenter, randomized, open-labeled and controlled IDE clinical study that demonstrated the superiority of Agili-C™ implant to the current surgical standard of care, debridement and microfracture in the knee joint CartiHeal Ltd, developer of implants for the treatment of cartilage and ...

Grünenthal Group

Grünenthal and NovaQuest enter agreement to advance the resiniferatoxin global Phase III program in osteoarthritis

Aachen, Germany, and Raleigh, North Carolina (ots) - Grünenthal and NovaQuest announced today that they have entered into an agreement to advance the global clinical Phase III programme of Grünenthal's asset resiniferatoxin (RTX). The investigational medicine is being developed with the aim of providing patients ...

Ithra

'Davos of digital wellbeing' gets underway with ambition to drive greater understanding of digital harms

Dhahran, Saudi Arabia (ots/PRNewswire) - - The inaugural Sync Digital Wellbeing Summit (29-30 March) will raise awareness of the hidden realities of our relationship with digital services - Leadership from IBM, UNESCO and Childnet amongst those speaking at sessions across the two-day Summit - Full Summit agenda can ...

Abcam plc

Abcam the most awarded company at 2022 industry awards

Cambridge, England (ots/PRNewswire) - CAMBRIDGE, England, March 25, 2022 Abcam (AIM:ABC); (NASDAQ:ABCM), today announced that it has received six recognitions from CiteAb at their annual industry awards, the highest of any participant evaluated this year. This record number of acknowledgments follows a year of substantial investment for Abcam to enable life sciences researchers from academia and industry to advance ...

Abcam

Abcam the most awarded company at 2022 industry awards

Cambridge, England (ots/PRNewswire) - CAMBRIDGE, England, March 25, 2022 Abcam (AIM:ABC); (NASDAQ:ABCM), today announced that it has received six recognitions from CiteAb at their annual industry awards, the highest of any participant evaluated this year. This record number of acknowledgments follows a year of substantial investment for Abcam to enable life sciences researchers from academia and industry to advance ...

MoonLake Immunotherapeutics AG

MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa with HiSCR75 as the primary endpoint

Zug, Switzerland (ots/PRNewswire) - - This Phase 2 study represents an important step in hidradenitis suppurativa ("HS") clinical development, as it will be the first to use the higher clinical response level of HiSCR75 as the primary endpoint - Expected to enroll over 200 patients with moderate-to-severe HS to ...